Gerald Finken Joins the IPHO Podcast

Gerald Finken, the founder of RxE2 and E2 services explains how he is using an efficient clinical supply chain process to deliver affordable, effective, and quality services. Gerald is following this one simple rule of disruptive innovation to improve patient centered care. He says, “Believe in your idea, have faith, and don’t go against collective…

Everyone Everywhere with Gerald Finken | Episode 04

Everyone Everywhere with Gerald Finken | Episode 04

Join us for Everyone Everywhere Episode 04; The Role and Impact of the CTRP® services, to hear from Dr. Kristina Schlecht about the knowledge she has gained through firsthand experience as a pharmacist, and how she is leading our industry forward as Chief Pharmacy Officer of RxE2. Connect with Tina on LinkedIn: https://www.linkedin.com/in/tina-schlecht/​ Connect with Gerald…

Webinar: The Benefits of Pharmacist-Led Clinical Trials

The Benefits of Pharmacist-Led Clinical Trials

This Fierce Biotech webinar focuses on how a pharmacist-led clinical trial model impacts the six key areas most relevant to clinical trials in today’s COVID and Decentralized Clinical Trial environment: • Regulations – GMP and GCP regulations versus state healthcare regulations ‍ • Recruiting – Clinical research participation as a healthcare option for all patients…

RxE2 Northstar Development Cycling

RxE2 CEO and Two-Time USA Cycling Masters Nationals Champion Gerald Finken Donates $27,500 to NorthStar Development Cycling Club

Fargo, ND, February 2, 2021— RxE2 CEO and two-time USA Cycling Masters National Cycling Champion, Gerald Finken, is once again helping young cyclists. RxE2 announced today that it will donate $27,500 to support the youth programs of the NorthStar Development Cycling Club. ‍ Mr. Finken’s current contribution will help to support the: training of young cyclists,…

RxE2 acquires Habitu

RxE2 Agrees to Acquire Habitu to Form the First AI Driven, Pharmacist-Led, Clinical Trial Platform

Fargo, ND, January 11, 2021 — RxE2, which is bringing the practice of pharmacy to clinical research, announced today it has agreed to acquire Habitu, an Israeli-based technology company.  Habitu focuses on people’s habits and behaviors to create a KyP engine enabled by artificial intelligence, improving patient outcomes by providing real time analyses of a…

State_Law_Position_Statement_RXE2

RxE2 State Law Position Statement

U.S. State Laws Govern the Dispensing, Labeling, and Counseling Requirements for Investigational New Drugs‍ When conducting clinical trials, sponsors have traditionally looked to 21 C.F.R. §312, and not state law, for guidance. Upon closer examination of state laws, however, it becomes clear that states throughout the country categorize Investigational New Drugs (“INDs”) as prescription drugs.…